Solid Biosciences Inc.
NASDAQ Global SelectTotal Valuation
Solid Biosciences Inc. carries a market capitalization of 736.40M, placing it among publicly traded companies globally. Its enterprise value stands at 692.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 736.40M |
| Enterprise Value | 692.68M |
Share Statistics
Solid Biosciences Inc. currently has 105.13M shares outstanding.
| Shares Outstanding | 105.13M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.81 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | -6.23 |
| P/OCF Ratio | -6.20 |
Financial Position
Solid Biosciences Inc. maintains a current ratio of 13.82, meaning it holds 13.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.82 |
| Quick Ratio | 13.21 |
| Debt / Equity | 5.39 |
| Debt / EBITDA | -0.10 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -65.50 |
| Return on Assets (ROA) | -56.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Solid Biosciences Inc.'s stock has gained approximately 19.87179% over the past 52 weeks. The 50-day moving average sits at 8.95, while the 200-day moving average is 7.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 19.87179% |
| 50-Day Moving Average | 8.95 |
| 200-Day Moving Average | 7.54 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -210.52M, while operating income came in at -212.15M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -212.15M |
| Pretax Income | -207.10M |
| Net Income | -207.10M |
| EBITDA | -210.52M |
| EBIT | -212.15M |
| Earnings Per Share (EPS) | -1.79 |
Balance Sheet
Solid Biosciences Inc. holds 377.68M in cash and equivalents against 20.16M in total debt, resulting in a net debt position of -159.39M. Total book value stands at 374.08M, with working capital of 366.52M providing operational flexibility.
| Cash & Cash Equivalents | 377.68M |
| Total Debt | 20.16M |
| Net Debt | -159.39M |
| Equity (Book Value) | 374.08M |
| Book Value Per Share | 3.56 |
| Working Capital | 366.52M |
Cash Flow
Solid Biosciences Inc. produced -186.84M in operating cash flow over the past twelve months. After subtracting -965,000.00 in capital expenditures, free cash flow totaled -187.81M - equivalent to -1.62 per share.
| Operating Cash Flow | -186.84M |
| Capital Expenditures | -965,000.00 |
| Free Cash Flow | -187.81M |
| FCF Per Share | -1.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -27.98 |
| FCF Yield | -16.04 |
Stock Splits
Solid Biosciences Inc.'s most recent stock split took place on October 28, 2022 with a 15:1 split ratio.
| Last Split Date | 10/28/2022 |
| Split Ratio | 15:1 |
Scores
Solid Biosciences Inc. posts an Altman Z-Score of 9.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.37 |